EUR 0.27
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 6.55 Million EUR | -45.38% |
2022 | 11.99 Million EUR | -36.46% |
2021 | 18.87 Million EUR | -44.94% |
2020 | 34.28 Million EUR | -47.28% |
2019 | 65.03 Million EUR | -43.39% |
2018 | 114.86 Million EUR | -23.65% |
2017 | 150.43 Million EUR | 23.68% |
2016 | 121.63 Million EUR | -32.03% |
2015 | 178.94 Million EUR | -18.92% |
2014 | 220.71 Million EUR | -18.6% |
2013 | 271.15 Million EUR | 13.37% |
2012 | 239.17 Million EUR | 85.28% |
2011 | 129.08 Million EUR | -9.69% |
2010 | 142.93 Million EUR | 41.22% |
2009 | 101.21 Million EUR | 50.62% |
2008 | 67.2 Million EUR | 29.24% |
2007 | 51.99 Million EUR | 39.28% |
2006 | 37.33 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 4.55 Million EUR | 0.0% |
2023 FY | 6.55 Million EUR | -45.38% |
2023 Q4 | 6.55 Million EUR | 0.0% |
2023 Q2 | 11.82 Million EUR | 0.0% |
2022 Q4 | 11.99 Million EUR | 0.0% |
2022 Q2 | 12.79 Million EUR | 0.0% |
2022 FY | 11.99 Million EUR | -36.46% |
2021 FY | 18.87 Million EUR | -44.94% |
2021 Q2 | 19 Million EUR | 0.0% |
2021 Q4 | 18.87 Million EUR | 0.0% |
2020 Q4 | 34.28 Million EUR | 0.0% |
2020 Q2 | 48.53 Million EUR | 0.0% |
2020 FY | 34.28 Million EUR | -47.28% |
2019 Q2 | 80.16 Million EUR | 0.0% |
2019 FY | 65.03 Million EUR | -43.39% |
2019 Q4 | 65.03 Million EUR | 0.0% |
2018 Q4 | 114.86 Million EUR | 0.0% |
2018 FY | 114.86 Million EUR | -23.65% |
2018 Q2 | 134.59 Million EUR | 0.0% |
2017 Q2 | 103.04 Million EUR | 0.0% |
2017 FY | 150.43 Million EUR | 23.68% |
2017 Q4 | 150.43 Million EUR | 0.0% |
2016 FY | 121.63 Million EUR | -32.03% |
2016 Q4 | 121.63 Million EUR | 0.0% |
2016 Q2 | 166.41 Million EUR | 0.0% |
2015 Q2 | 196.27 Million EUR | 0.0% |
2015 FY | 178.94 Million EUR | -18.92% |
2015 Q4 | 178.94 Million EUR | 0.0% |
2014 Q2 | 245.75 Million EUR | 0.0% |
2014 FY | 220.71 Million EUR | -18.6% |
2014 Q4 | 220.71 Million EUR | 0.0% |
2013 Q2 | 298.29 Million EUR | 0.0% |
2013 FY | 271.15 Million EUR | 13.37% |
2013 Q4 | 271.15 Million EUR | 0.0% |
2012 Q2 | 258.46 Million EUR | 0.0% |
2012 FY | 239.17 Million EUR | 85.28% |
2012 Q4 | 239.17 Million EUR | 0.0% |
2011 Q2 | 133.29 Million EUR | 0.0% |
2011 FY | 129.08 Million EUR | -9.69% |
2011 Q4 | 129.08 Million EUR | 0.0% |
2010 FY | 142.93 Million EUR | 41.22% |
2010 Q4 | 142.93 Million EUR | 0.0% |
2010 Q2 | 97.33 Million EUR | 0.0% |
2009 FY | 101.21 Million EUR | 50.62% |
2009 Q4 | 101.21 Million EUR | 0.0% |
2008 FY | 67.2 Million EUR | 29.24% |
2007 FY | 51.99 Million EUR | 39.28% |
2006 FY | 37.33 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | 55.472% |
ABIVAX Société Anonyme | 327.06 Million EUR | 97.997% |
Adocia SA | 24.95 Million EUR | 73.754% |
Aelis Farma SA | 26.28 Million EUR | 75.077% |
Biophytis S.A. | 11.93 Million EUR | 45.124% |
Advicenne S.A. | 12.4 Million EUR | 47.207% |
genOway Société anonyme | 31.84 Million EUR | 79.43% |
IntegraGen SA | 8 Million EUR | 18.129% |
Medesis Pharma S.A. | 1.92 Million EUR | -240.024% |
Neovacs S.A. | 47.53 Million EUR | 86.22% |
NFL Biosciences SA | 3.97 Million EUR | -64.961% |
Plant Advanced Technologies SA | 14.91 Million EUR | 56.078% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -74.817% |
Sensorion SA | 46.49 Million EUR | 85.912% |
Theranexus Société Anonyme | 7.23 Million EUR | 9.502% |
TME Pharma N.V. | 2.49 Million EUR | -162.947% |
Valbiotis SA | 33.24 Million EUR | 80.3% |
TheraVet SA | 7.53 Million EUR | 13.063% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | 81.431% |
argenx SE | 4.11 Billion EUR | 99.841% |
BioSenic S.A. | 9.55 Million EUR | 31.478% |
Celyad Oncology SA | 16.28 Million EUR | 59.772% |
DBV Technologies S.A. | 165.65 Million USD | 96.046% |
Galapagos NV | 4.35 Billion EUR | 99.85% |
Genfit S.A. | 173.87 Million EUR | 96.233% |
GeNeuro SA | 6.31 Million EUR | -3.756% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 86.263% |
Innate Pharma S.A. | 184.19 Million EUR | 96.444% |
Inventiva S.A. | 69.13 Million EUR | 90.526% |
MaaT Pharma SA | 42.93 Million EUR | 84.743% |
MedinCell S.A. | 36.94 Million EUR | 82.272% |
Nanobiotix S.A. | 93.89 Million EUR | 93.024% |
Onward Medical N.V. | 43.62 Million EUR | 84.987% |
Oryzon Genomics S.A. | 106.9 Million EUR | 93.873% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 92.002% |
Pharming Group N.V. | 426.33 Million EUR | 98.464% |
Poxel S.A. | 4.82 Million EUR | -35.808% |
GenSight Biologics S.A. | 9.08 Million EUR | 27.919% |
Transgene SA | 45.21 Million EUR | 85.514% |
Financière de Tubize SA | 1.92 Billion EUR | 99.659% |
UCB SA | 15.53 Billion EUR | 99.958% |
Valneva SE | 469.39 Million EUR | 98.605% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | 78.754% |